Bioequivalence and pharmacokinetic study of two oral formulations of ciprofloxacin tablets in healthy male volunteers

Journal of Applied Research

Volumn 7, Issue 2, 2007, Pages 150-157

  Azad, Mohammad Abul Kalam ^a   Ullah, Ashik ^a   Latif, A H M Mahbub ^a   Hasnat, Abul ^a  

^a UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

Bioavailability; Bioequivalence; Ciprofloxacin; Pharmacokinetic

Indexed keywords

CIPROFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONFIDENCE INTERVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STUDENT T TEST; TABLET; ULTRAVIOLET SPECTROSCOPY;

EID: 34447513141     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bauernfeind A, Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983;2:111-115.
2. Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984;25:319-326.
3. Goodman LJ, Fliegelman RM, Trenholme GM, Kaplan RL. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother. 1984;25:504-506.
4. Van Caekenberghe DL, Pattyn SR. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984;25:518-521.
5. Borner K, Lode H, Elvers A. Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1982;22:949-953.
6. Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicro Agents Chemother. 1983;24:784-786.
7. Keller I, Lubasch A, Rau M. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin after a single in healthy volunteers [abstract 30]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 26-29, 1999.
8. Healy D, Brodbeck M, Clendening C. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996;40:6-10.
9. Mueller B, Brierton G, Abel S. Effect of enteral feeding with ensure on the bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994; 38:2101-2105.
10. Noer B, Angaran D. The effect of enteral feedings on ciprofloxacin pharmacokinetics. Pharmacotherapy. 1990;10:254.
11. nd ed. 2003. Boca Raton, FL: Chapman & Hall/CRC.
12. Food and Drug Administration. Tequin Tablets (Gatifloxacin), Tequin Injection (Gatifloxacin). Washington, DC: Department of Health and Human Services; 1999.
13. Hutchinson TA, Shahan DR, Anderson ML. Drugdex System. Englewood, CO: Micromedex; 2001.
14. Panacea Biotec Ltd. MYGAT (Gatifloxacin infusion- 2 mg/mL). New Delhi, India; 2003.
15. Nakashima M, Uematsu T, Kosuge K. Single and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995;39:2635-2640.
16. Liang H, Kays M, Sowinski K. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr. 2002;772:53-63.
17. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York; Dekker, 1982:433-434.
18. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2005. Available at: http://www.r-project.org. Accessed April 25, 2007.
19. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville, Md; 2002.
20. Hauschke D, Steinijans VW, Diletti EA. Distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990;28:72-78.
21. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, Md, 2001.
22. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther. 1991;29:394-399.